DNA methylation profiling of myelodysplastic syndrome hematopoietic progenitor cells during in vitro lineage-specific differentiation

Experimental Hematology

Volumn 35, Issue 5, 2007, Pages 712-723

  Hopfer, Olaf ^a   Komor, Martina ^b   Koehler, Ina Sabine ^a   Schulze, Matthias ^c   Hoelzer, Dieter ^b   Thiel, Eckhard ^a   Hofmann, Wolf Karsten ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^c GERMAN INSTITUTE OF HUMAN NUTRITION   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD34 ANTIGEN; CHECKPOINT KINASE 2; DEATH ASSOCIATED PROTEIN KINASE; MESSENGER RNA; PROTEIN; PROTEIN P14; PROTEIN P15; PROTEIN P16; PROTEIN P73; PROTEIN RARB; SURVIVIN; UNCLASSIFIED DRUG; WT1 PROTEIN;

ADULT; AGED; APOPTOSIS; ARTICLE; BONE MARROW; CELL DIFFERENTIATION; CELL LINEAGE; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; DNA REPAIR; EPIGENETICS; ERYTHROPOIESIS; FEMALE; GENE EXPRESSION; GRANULOPOIESIS; HEMATOPOIESIS; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; MICROARRAY ANALYSIS; MYELODYSPLASTIC SYNDROME; NUCLEOTIDE SEQUENCE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; SCORING SYSTEM;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD34; CELL DIFFERENTIATION; CELL LINEAGE; CYCLIN-DEPENDENT KINASE INHIBITOR PROTEINS; DNA METHYLATION; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELLS; HUMANS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASM PROTEINS; NUCLEAR PROTEINS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; POLYMERASE CHAIN REACTION; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; WT1 PROTEINS;

EID: 34247331040     PISSN: 0301472X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.exphem.2007.01.054     Document Type: Article

References (52)

1. Hofmann W.K., and Koeffler H.P. Myelodysplastic syndrome. Annu Rev Med 56 (2005) 1-16
2. Kitagawa M., Saito I., Kuwata T., et al. Overexpression of tumor necrosis factor (TNF)-alpha and interferon (IFN)-gamma by bone marrow cells from patients with myelodysplastic syndromes. Leukemia 11 (1997) 2049-2054
3. Hofmann W.K., Kalina U., Wagner S., et al. Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes. Exp Hematol 27 (1999) 395-400
4. Jones P.A., and Baylin S.B. The fundamental role of epigenetic events in cancer. Nat Rev Genet 3 (2002) 415-428
5. Sakai T., Toguchida J., Ohtani N., Yandell D.W., Rapaport J.M., and Dryja T.P. Allele-specific hypermethylation of the retinoblastoma tumor-suppressor gene. Am J Hum Genet 48 (1991) 880-888
6. Bennett J.M., Catovsky D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51 (1982) 189-199
7. Uchida T., Kinoshita T., Nagai H., et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 90 (1997) 1403-1409
8. Quesnel B., Guillerm G., Vereecque R., et al. Methylation of the p15(INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 91 (1998) 2985-2990
9. Daskalakis M., Nguyen T.T., Nguyen C., et al. Demethylation of a hypermethylated P15/INK4B gene in patients with myelodysplastic syndrome by 5-Aza-2′-deoxycytidine (decitabine) treatment. Blood 100 (2002) 2957-2964
10. Toyota M., Ahuja N., Suzuki H., et al. Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 59 (1999) 5438-5442
11. Toyota M., Kopecky K.J., Toyota M.O., Jair K.W., Willman C.L., and Issa J.P. Methylation profiling in acute myeloid leukemia. Blood 97 (2001) 2823-2829
12. Herman J.G., Graff J.R., Myohanen S., Nelkin B.D., and Baylin S.B. Methylation-specific pcr: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci U S A 93 (1996) 9821-9826
13. Hofmann W.K., Tsukasaki K., Takeuchi N., Takeuchi S., and Koeffler H.P. Methylation analysis of cell cycle control genes in adult T-cell leukemia/lymphoma. Leuk Lymphoma 42 (2001) 1107-1109
14. Roman-Gomez J., Jimenez-Velasco A., Castillejo J.A., et al. Promoter hypermethylation of cancer-related genes: a strong independent prognostic factor in acute lymphoblastic leukemia. Blood 104 (2004) 2492-2498
15. Corn P.G., Kuerbitz S.J., van Noesel M.M., et al. Transcriptional silencing of the p73 gene in acute lymphoblastic leukemia and Burkitt's lymphoma is associated with 5′ CpG island methylation. Cancer Res 59 (1999) 3352-3356
16. Kato N., Fujimoto H., Yoda A., et al. Regulation of Chk2 gene expression in lymphoid malignancies: involvement of epigenetic mechanisms in Hodgkin's lymphoma cell lines. Cell Death Differ 11 (2004) S153-S161
17. Uehara E., Takeuchi S., Tasaka T., et al. Aberrant methylation in promoter-associated CpG islands of multiple genes in therapy-related leukemia. Int J Oncol 23 (2003) 693-696
18. Yu J., Zhang H., Gu J., et al. Methylation profiles of thirty four promoter-CpG islands and concordant methylation behaviours of sixteen genes that may contribute to carcinogenesis of astrocytoma. BMC Cancer 4 (2004) 65
19. Esteller M. Profiling aberrant DNA methylation in hematologic neoplasms: a view from the tip of the iceberg. Clin Immunol 109 (2003) 80-88
20. Esteller M., Guo M., Moreno V., et al. Hypermethylation-associated inactivation of the cellular retinol-binding-protein 1 gene in human cancer. Cancer Res 62 (2002) 5902-5905
21. Hofmann W.K., de Vos S., Komor M., Hoelzer D., Wachsman W., and Koeffler H.P. Characterization of gene expression of CD34+ cells from normal and myelodysplastic bone marrow. Blood 100 (2002) 3553-3560
22. Komor M., Guller S., Baldus C.D., et al. Transcriptional profiling of human hematopoiesis during in vitro lineage-specific differentiation. Stem Cells 23 (2005) 1154-1169
23. Brazma A., Hingamp P., Quackenbush J., et al. Minimum information about a microarray experiment (MIAME)-toward standards for microarray data. Nat Genet 29 (2001) 365-371
24. Esteller M., Tortola S., Toyota M., et al. Hypermethylation-associated inactivation of p14(ARF) is independent of p16(INK4a) methylation and p53 mutational status. Cancer Res 60 (2000) 129-133
25. House M.G., Guo M., Iacobuzio-Donahue C., and Herman J.G. Molecular progression of promoter methylation in intraductal papillary mucinous neoplasms (IPMN) of the pancreas. Carcinogenesis 24 (2003) 193-198
26. Wong I.H., Ng M.H., Huang D.P., and Lee J.C. Aberrant p15 promoter methylation in adult and childhood acute leukemias of nearly all morphologic subtypes: potential prognostic implications. Blood 95 (2000) 1942-1949
27. Herman J.G., Umar A., Polyak K., et al. Incidence and functional consequences of hMLH1 promoter hypermethylation in colorectal carcinoma. Proc Natl Acad Sci U S A 95 (1998) 6870-6875
28. Katzenellenbogen R.A., Baylin S.B., and Herman J.G. Hypermethylation of the DAP-kinase CpG island is a common alteration in B-cell malignancies. Blood 93 (1999) 4347-4353
29. Tort F., Hernandez S., Bea S., et al. CHK2-decreased protein expression and infrequent genetic alterations mainly occur in aggressive types of non-Hodgkin lymphomas. Blood 100 (2002) 4602-4608
30. Yu J., Zhang H.Y., Ma Z.Z., Lu W., Wang Y.F., and Zhu J.D. Methylation profiling of twenty-four genes and the concordant methylation behaviours of nineteen genes that may contribute to hepatocellular carcinogenesis. Cell Res 13 (2003) 319-333
31. Tohyama K., Tohyama Y., Nakayama T., Ueda T., Nakamura T., and Yoshida Y. A novel factor-dependent human myelodysplastic cell line, MDS92, contains haemopoietic cells of several lineages. Br J Haematol 91 (1995) 795-799
32. Bruno L., Hoffmann R., McBlane F., et al. Molecular signatures of self-renewal, differentiation, and lineage choice in multipotential hemopoietic progenitor cells in vitro. Mol Cell Biol 24 (2004) 741-756
33. Hardie L.J., Darnton S.J., Wallis Y.L., et al. p16 expression in Barrett's esophagus and esophageal adenocarcinoma: association with genetic and epigenetic alterations. Cancer Lett 217 (2005) 221-230
34. Tamaki H., Ogawa H., Ohyashiki K., et al. The Wilms' tumor gene WT1 is a good marker for diagnosis of disease progression of myelodysplastic syndromes. Leukemia 13 (1999) 393-399
35. Svensson E., Eriksson H., Gekas C., Olofsson T., Richter J., and Gullberg U. DNA-binding dependent and independent functions of WT1 protein during human hematopoiesis. Exp Cell Res 308 (2005) 211-221
36. Ellisen L.W., Carlesso N., Cheng T., Scadden D.T., and Haber D.A. The Wilms tumor suppressor WT1 directs stage-specific quiescence and differentiation of human hematopoietic progenitor cells. EMBO J 20 (2001) 1897-1909
37. Werner H., Re G.G., Drummond I.A., et al. Increased expression of the insulin-like growth factor I receptor gene, IGF1R, in Wilms tumor is correlated with modulation of IGF1R promoter activity by the WT1 Wilms tumor gene product. Proc Natl Acad Sci U S A 90 (1993) 5828-5832
38. Zhang P., Wang J., Gao W., Yuan B.Z., Rogers J., and Reed E. CHK2 kinase expression is down-regulated due to promoter methylation in non-small cell lung cancer. Mol Cancer 3 (2004) 14
39. Lukas C., Falck J., Bartkova J., Bartek J., and Lukas J. Distinct spatiotemporal dynamics of mammalian checkpoint regulators induced by DNA damage. Nat Cell Biol 5 (2003) 255-260
40. Kastan M.B., and Bartek J. Cell-cycle checkpoints and cancer. Nature 432 (2004) 316-323
41. Lee S.B., Kim S.H., Bell D.W., et al. Destabilization of CHK2 by a missense mutation associated with Li-Fraumeni syndrome. Cancer Res 61 (2001) 8062-8067
42. Craig A.L., and Hupp T.R. The regulation of CHK2 in human cancer. Oncogene 23 (2004) 8411-8418
43. Hofmann W.K., Miller C.W., Tsukasaki K., et al. Mutation analysis of the DNA-damage checkpoint gene CHK2 in myelodysplastic syndromes and acute myeloid leukemias. Leuk Res 25 (2001) 333-338
44. Bartkova J., Horejsi Z., Koed K., et al. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 434 (2005) 864-870
45. Ambrosini G., Adida C., and Altieri D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3 (1997) 917-921
46. Altieri D.C. Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22 (2003) 8581-8589
47. Li F., Ambrosini G., Chu E.Y., et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 396 (1998) 580-584
48. Fukuda S., and Pelus L.M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bone marrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 98 (2001) 2091-2100
49. Badran A., Yoshida A., Wano Y., et al. Expression of the anti-apoptotic gene survivin in myelodysplastic syndrome. Int J Oncol 22 (2003) 59-64
50. Invernizzi R., Travaglino E., Lunghi M., et al. Survivin expression in acute leukemias and myelodysplastic syndromes. Leuk Lymphoma 45 (2004) 2229-2237
51. Yamamoto K., Abe S., Nakagawa Y., et al. Expression of IAP family proteins in myelodysplastic syndromes transforming to overt leukemia. Leuk Res 28 (2004) 1203-1211
52. Gurbuxani S., Xu Y., Keerthivasan G., Wickrema A., and Crispino J.D. Differential requirements for survivin in hematopoietic cell development. Proc Natl Acad Sci U S A 102 (2005) 11480-11485